Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RG1068 (Synthetic Human Secretin)
RG1068 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Currently treated with SSRI | EXPERIMENTAL | - |
| Not currently treated with SSRI | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RG1068 (synthetic human secretin) | DRUG | Single-dose, IV infusion |
Inclusion Criteria: * History of pancreatitis * Medically stable * Able to give informed consent Exclusion Criteria: * Prior history of pancreatic resection * Prior history of pancreatic duct drainage procedure * Presence of a pancreatic stent * Unstable cardiovascular disease * Any contraindicat...
Top 3 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 3 | PHASE3 | Xanomeline and trospium chloride, KarX-EC |
| Definium Therapeutics, Inc. | DFTX | 1 | PHASE2 | DT402 |
| MapLight Therapeutics, Inc. | MPLT | 1 | PHASE2 | ML-004 |
RG1068 is a synthetic human secretin developed by Repligen Corporation. It has been studied in pancreatitis imaging and in psychiatric and neurodevelopmental conditions including autism and obsessive compulsive disorder. The program's lead Phase 3 trial evaluated synthetic human secretin-enhanced MRCP in patients with abnormalities of the pancreas.
RG1068 has been studied for imaging of the pancreas in patients with pancreatitis, and separately in autism and obsessive compulsive disorder. Its most advanced evaluation is a completed Phase 3 trial of synthetic human secretin-enhanced MRCP in subjects with abnormalities of the pancreas, which enrolled 258 participants.
RG1068 is developed by Repligen Corporation, which trades on the Nasdaq under the ticker RGEN. Repligen sponsored the clinical program for synthetic human secretin across pancreatic imaging, autism, and obsessive compulsive disorder indications.
RG1068 has reached Phase 3. A Phase 3 trial of synthetic human secretin-enhanced MRCP in patients with pancreatic abnormalities has been completed, and a Phase 3 study of synthetic human secretin in children with autism has also been completed. No trials are currently listed as active.
RG1068 has been studied in completed trials including NCT00660335, a Phase 3 trial of synthetic human secretin-enhanced MRCP in pancreatitis that enrolled 258 subjects, NCT00216294, a Phase 2 safety study in obsessive compulsive disorder, and NCT00036244, a Phase 3 study of synthetic human secretin in children with autism.
Yes. RG1068 is also known as synthetic human secretin, and the two names refer to the same investigational agent. Repligen Corporation developed RG1068 under both designations, and its trials are listed under the synthetic human secretin name in registry records.